Kobo Biotech Limited is a specialized Indian pharmaceutical company focused on the manufacture of **Active Pharmaceutical Ingredients (APIs)** and **Bulk Drugs** utilizing advanced **Fermentation technology**. While the company is strategically positioned within a high-growth sector of the Indian healthcare landscape, it is currently navigating a period of severe financial distress, operational suspension, and formal insolvency proceedings. --- ### **Current Corporate Status: Insolvency and Governance** Kobo Biotech is presently undergoing a **Corporate Insolvency Resolution Process (CIRP)**. This process was initiated following a petition filed by **JM Financial Asset Reconstruction Company Limited** under **Section 7** of the **Insolvency and Bankruptcy Code (IBC), 2016**. * **Legal Standing:** The **National Company Law Tribunal (NCLT)**, Hyderabad, formally admitted the insolvency petition on **August 13, 2024**. * **Suspension of Board:** In accordance with the IBC, the powers of the Board of Directors are currently **suspended**, and the company’s affairs are managed by a court-appointed professional. * **Resolution Leadership:** As of **January 2025**, **Ms. Namrata Amol Randeri** serves as the **Resolution Professional (RP)**, overseeing the restructuring process. * **Key Personnel Vacancies:** The company faces significant administrative gaps, including the resignation of the **Company Secretary & Compliance Officer** in **June 2024**. --- ### **Manufacturing Infrastructure and Asset Profile** The company’s physical footprint consists of two primary sites, both of which are currently subject to heavy encumbrances by lenders. * **Solapur Plant (Maharashtra):** Located at Plot No. **E-2/B-2**, MIDC Chincholi, this facility covers approximately **80,000 square metres**. Management reported in **February 2024** that operations at this site **cannot be resumed** due to prevailing regulatory and financial constraints. * **Medak Facility (Andhra Pradesh):** Situated in Yawapur Village, this site spans **18 acres (7.28 hectares)** across two survey plots and includes integrated plant, machinery, and buildings. **Security Interest and Hypothecation:** Substantially all company assets are held under **Pari-passu charge** or hypothecation by a consortium of lenders including **Axis Bank, PNB, and Karur Vysya Bank**. | Asset Category | Scope of Security | | :--- | :--- | | **Fixed Assets** | Land, buildings, plant, machinery, and fixtures at both Solapur and Medak sites. | | **Current Assets** | All movable goods (present and future) including raw materials and stock-in-process. | | **Financial Assets** | All present and future receivables, book debts, claims, and contracts. | | **Other Movables** | Computers, vehicles, cranes, tools, and consumable stores. | --- ### **Financial Performance and Capital Structure** The company has reported consistent net losses and a near-total cessation of revenue-generating activities. **Standalone Financial Summary:** | Particulars (Rs. in Lakhs) | FY 2022-23 | FY 2021-22 | | :--- | :--- | :--- | | **Total Income** | **1.52** | **1.66** | | **EBITDA** | **(148.13)** | **(1,048.50)** | | **Profit / (Loss) After Tax** | **(555.34)** | **(1,522.59)** | | **Earnings Per Share (EPS)** | **(2.33)** | **(6.39)** | **Equity and Ownership:** * **Share Capital:** As of March 31, 2023, the paid-up capital stands at **Rs. 2,382.50 Lakhs**, consisting of **2,38,25,000 equity shares** (Face Value **Rs. 10**). * **Promoter Holding:** **Arch Pharmalabs Limited** is the primary promoter, holding **1,07,09,100 shares (44.95%)**. * **Promoter Contagion Risk:** The promoter entity, Arch Pharmalabs, was also admitted to **Section 7 IBC** proceedings in **May 2024** for a default of **₹134.99 Crore**, though a stay was later granted by the NCLAT. --- ### **Creditor Composition and Debt Obligations** The company’s debt has largely been assigned to asset reconstruction companies. The **Committee of Creditors (CoC)** is dominated by a single entity: | Creditor Name | Voting Share (%) | | :--- | :--- | | **JM Financial Asset Reconstruction Company Ltd** | **90.97%** | | **Indian Overseas Bank** | **5.96%** | | **Canbank Factors Limited** | **1.93%** | | **Omkara Assets Reconstruction Private Limited** | **0.88%** | **Debt Servicing Issues:** * The company has **ceased providing for interest costs** on loans assigned to JM Financial ARC. * There are significant **statutory defaults** exceeding six months for **Provident Fund, ESI, Income Tax, GST, and Customs Duty**. --- ### **Strategic Market Context and Industry Outlook** Despite current operational halts, Kobo Biotech’s underlying business model is designed to align with significant tailwinds in the Indian pharmaceutical sector. **Market Projections:** * **Indian API Market:** Estimated to reach **US$ 27.9 Billion** by 2023. * **Growth Rate:** The industry is projected to maintain a **~9% CAGR** through 2024. * **Export Potential:** India’s API export market was valued at **US$ 3.5 Billion** in 2020. **Strategic Levers for Potential Recovery:** * **'China + 1' Strategy:** Positioning as an alternative global supplier to reduce reliance on Chinese manufacturing. * **PLI Scheme:** Potential to leverage the Government of India’s **Production Linked Incentive** scheme for **Critical Key Starting Materials (KSMs)** and APIs. * **Import Substitution:** Focusing on domestic manufacturing resilience to capture value from high-value molecules. --- ### **Critical Risk Factors for Investors** * **Operational Cessation:** The primary manufacturing site at Solapur remains non-functional with no immediate timeline for resumption. * **Insolvency Outcome:** The future of the company depends entirely on the **CIRP** outcome; failure to find a resolution applicant could lead to liquidation. * **Regulatory Stringency:** The company is subject to rigorous domestic and international pharmaceutical regulations; any failure to meet these standards during a restart would be terminal. * **Macroeconomic & Legal Risks:** Exposure to **currency fluctuations**, **patent litigations**, and evolving **pricing guidelines** in the Indian market. * **Social Liabilities:** Potential financial liabilities arising from public health risks associated with pharmaceutical manufacturing in emerging markets.